Brief Report: Relationship Between Tumor Volume and Clinical Outcomes in Relapsed SCLC [0.03%]
简报：肿瘤体积与小细胞肺癌复发患者临床结局之间的关系
Matthew Lu,Hayden Byrd,Heidi Chen et al.
Matthew Lu et al.
Introduction: For patients with limited-stage SCLC (LS-SCLC), tumor burden is a predictor of clinical outcomes, but there are no known data exploring whether tumor burden is a predictor of clinical outcomes in relapsed SC...
Central Nervous System Progression in Patients Receiving ALK-Targeted Central Nervous System-Penetrable Tyrosine Kinase Inhibitors: Treatment Patterns and Outcomes [0.03%]
针对中枢神经系统可穿透的靶向ALK酪氨酸激酶抑制剂治疗患者的中枢神经系统进展：治疗模式和结局
Surbhi Singhal,Caressa Hui,Joel W Neal et al.
Surbhi Singhal et al.
Introduction: Central nervous system (CNS) metastases are common in ALK-rearranged NSCLC. The optimal treatment strategy for patients who develop CNS progression during treatment with CNS-penetrable ALK tyrosine kinase in...
DLL3 Immunohistochemical Expression in Neuroendocrine-Transformed EGFR-Mutant Lung Cancer and Two Cases of Tarlatamab Therapy [0.03%]
神经内分泌转化EGFR突变型肺癌中的DLL3免疫组织化学表达及2例Tarlatamab治疗病例报告
Jacqueline V Aredo,Surbhi Singhal,Gerald J Berry et al.
Jacqueline V Aredo et al.
Introduction: Histologic transformation to high-grade neuroendocrine carcinoma occurs in resistance to EGFR targeted treatment in approximately 3% to 4% of patients with EGFR-mutant lung cancer and is associated with poor...
ICTIS: A Novel Scoring System to Assess the Inclusivity of Advanced NSCLC Immunotherapy Trials [0.03%]
ICTIS：一种评估晚期非小细胞肺癌免疫治疗试验包容性的新型评分系统
Kira Nguyen,Ashley Wei,Srinivas Govindan et al.
Kira Nguyen et al.
Introduction: Immunotherapy has revolutionized the treatment of NSCLC. However, trials that led to approval of these agents and ongoing trials often include overly included overly restrictive exclusion criteria, limiting ...
Safety, Efficacy, and Central Nervous System Control in Patients with High Baseline Risk Factors Treated with Tarlatamab for SCLC or Extrapulmonary Small Cell Carcinoma [0.03%]
泰拉塔马布治疗高基线风险因素SCLC或肺外小细胞癌患者的安安全性、有效性和中枢神经系统控制能力研究
Sanjana Mullangi,Manidhar Reddy Lekkala,Sarah Blocker et al.
Sanjana Mullangi et al.
Introduction: SCLC remains the most aggressive lung cancer with a poor prognosis. Tarlatamab, a bispecific T-cell engager, is approved for use in extensive-stage SCLC after progression on a platinum-based chemotherapy on ...
AdvanTIG-204: A Phase 2, Randomized, Open-Label Study of Ociperlimab Plus Tislelizumab and Concurrent Chemoradiotherapy Versus Tislelizumab and Concurrent Chemotherapy Versus Concurrent Chemoradiotherapy in First-Line Limited-Stage SCLC [0.03%]
AdvanTIG-204：一项一线局限期小细胞肺癌患者接受_ociperlimab_联合_tislelizumab_及同期放化疗、单用_tislelizumab_及同期化疗和单纯同期放化疗的II期、随机、开放标签研究
Youling Gong,Qingsong Pang,Rong Yu et al.
Youling Gong et al.
Introduction: Patients with limited-stage SCLC (LS-SCLC) have a substantial unmet clinical need for new treatments that delay disease progression and prolong survival. ...
Cost-Effectiveness of Durvalumab After Chemoradiotherapy in Limited-Stage SCLC [0.03%]
度伐利尤单抗巩固治疗局限期小细胞肺癌的经济学价值评估
Sheng-Han Tsai,Jui-Hung Tsai,Li-Jun Chen et al.
Sheng-Han Tsai et al.
Introduction: In the ADRIATIC trial, durvalumab consolidation therapy improved the overall survival and progression-free survival of patients with limited-stage SCLC responding to chemoradiotherapy. Based on the data, we ...
Characteristics of Short-Term Survivors With ALK or ROS1-Altered Metastatic NSCLC [0.03%]
ALK或ROS1重排转移性非小细胞肺癌短期预后不佳患者的临床特征分析
Kai-Lin Liu,Alex Watts,Connor B Grady et al.
Kai-Lin Liu et al.
Introduction: The prognostic significance of baseline and on-treatment brain and liver metastasis in ALK+ or ROS1+ metastatic NSCLC (mNSCLC) remains unclear. As we consider intensification strategies, it is critical to id...
Incorporating High-Risk Individuals Beyond Smoking History Into Lung Cancer Screening in Hong Kong: A Cost-Effectiveness Study [0.03%]
将吸烟史之外的高危人群纳入香港肺癌筛查：一项成本效益研究
Herbert Ho-Fung Loong,Xuanqi Pan,Carlos K H Wong et al.
Herbert Ho-Fung Loong et al.
Introduction: Lung cancer (LC) accounts for 26.4% of all cancer deaths in Hong Kong (HK). Lung cancer screening (LCS) with low-dose computed tomography (LDCT) can reduce LC mortality. The cost-effectiveness of LDCT screen...
A Retrospective Observational Cohort Study of Lung Cancer Screening Outcomes Among U.S. Blacks and Whites [0.03%]
美国黑人和白人的肺癌筛查结果回顾性观察队列研究
Giorgi Sabakhtarishvili,Mitchell B Karpman,Rahul Mishra et al.
Giorgi Sabakhtarishvili et al.
Background: Mortality from lung cancer is reduced with low-dose computed tomography (LDCT) screening in high-risk persons. But screening uptake is low, especially among Black persons. Previous reports of LDCT had low part...